Linq Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-07-2024
- Paid Up Capital ₹ 5.00 M
as on 11-07-2024
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 17.28%
(FY 2022)
- Profit -19.03%
(FY 2022)
- Ebitda 31.69%
(FY 2022)
- Net Worth 99.18%
(FY 2022)
- Total Assets -17.36%
(FY 2022)
About Linq Therapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Jehangir Jehangir, Uma Divate, Pathik Divate, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999PN2015PTC156595
- Company No.
156595
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Linq Therapeutics?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uma Divate  | Director | 29-Sep-2015 | Current |
| Pathik Divate | Director | 29-Sep-2015 | Current |
| Cowasji Jehangir | Director | 25-Nov-2020 | Current |
| Jehangir Jehangir | Director | 29-Sep-2015 | Current |
| Geeta Divate | Director | 25-Nov-2020 | Current |
Financial Performance and Corporate Structure Insights of Linq Therapeutics.
Linq Therapeutics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 17.28% increase. The company also saw a substantial fall in profitability, with a 19.03% decrease in profit. The company's net worth Soared by an impressive increase of 99.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Linq Therapeutics?
In 2019, Linq Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jehangir Clinical Developement Centre Private LimitedActive 18 years 3 monthsJehangir Jehangir, Uma Divate and 3 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Linq Therapeutics?
Linq Therapeutics has a workforce of 5 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Linq Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Linq Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
